What is the typical dosing for NA-931?

Oral, from trial registrations. No independently published protocol exists.. Common doses observed in research: 60 mg once daily, 120 mg once daily, 150 mg once daily. Duration: 28 days in Phase 1, 13 weeks in Phase 2. Administration: Oral capsule or tablet, once daily.

Weight Loss

NA-931

Also known as: Bioglutide, cyclic glycine-proline, cGP, cyclo(Gly-Pro), NA931

Clinical Trials

•NA-931 (Bioglutide) is cyclic glycine-proline, a two-amino-acid ring that occurs naturally as a breakdown product of IGF-1. Its developer, Biomed Industries, describes it as an oral once-daily agonist at four receptors at once - IGF-1, GLP-1, GIP and glucagon - and has reported 13 to 15 percent weight loss in a 126-person Phase 2 trial.
•Status: Phase 2 completed in Australia April 2025, no results posted. A third trial (NCT06732245) is registered but not yet recruiting. No registered Phase 3 despite company statements. No FDA approval, no orphan designation found, no evidence of a US IND.. Evidence level: Phase II Completed, Unpublished.
•Typical dose: 120 mg daily, oral (Once daily). Oral capsule or tablet, once daily.
•Researched for: Weight loss, appetite regulation.

Key Facts: NA-931

Category: Weight Loss
FDA Status: Not FDA Approved
Clinical Status: Phase 2 completed in Australia April 2025, no results posted. A third trial (NCT06732245) is registered but not yet recruiting. No registered Phase 3 despite company statements. No FDA approval, no orphan designation found, no evidence of a US IND.
Administration: Oral capsule or tablet, once daily
Typical Dose: 120 mg daily, oral
Frequency: Once daily
Duration: 28 days in Phase 1, 13 weeks in Phase 2

Also Known As

Bioglutide, cyclic glycine-proline, cGP, cyclo(Gly-Pro), NA931

Mechanism of Action

Cyclic glycine-proline is a diketopiperazine: glycine and proline joined into a small ring, 154 daltons, roughly a thirtieth the size of tirzepatide or retatrutide. The independent literature, mostly from Jian Guan's group in Auckland, describes a single mechanism: cGP competes with IGF-1 for binding to IGFBP-3, which frees up IGF-1 that was otherwise bound and inactive. That is a bioavailability effect, studied for stroke recovery, Parkinson's and blood pressure rather than for weight. Biomed's own patent filing (WO2025160184A1) goes much further, claiming the same molecule is a 'quadruple receptor agonist' at IGF-1, GLP-1, GIP and glucagon receptors. That claim is worth understanding properly, because it is the entire basis of the weight-loss story. GLP-1, GIP and glucagon receptors are class B GPCRs, the kind that normally need a thirty-plus residue peptide wrapping into the receptor's binding groove to switch on. A 154-dalton ring activating all three would be a genuinely significant pharmacological finding. No independent group has reported it. Searching PubMed for cyclic glycine-proline alongside GLP-1 returns nothing at all.

Research Summary

There are no peer-reviewed publications on NA-931. Not one. Everything in circulation is a conference abstract, and the abstracts carrying the efficacy numbers list Biomed's CEO as sole author with conflicts declared as 'None'. Two trials have completed, both run entirely in Australia: a 74-person Phase 1 (NCT06615700, completed September 2024) and a 126-person Phase 2 (NCT06564753, completed April 2025). Neither has results posted. A third trial (NCT06732245) would run in the US, Australia and New Zealand, but has not started recruiting. The reported weight loss is where this gets difficult. The same 126-person Phase 2 has been presented three times with three different numbers: 14.8 percent at ADA in June 2025, 13.8 percent at ENDO in July, and 13.8 percent with a different placebo-adjusted figure in a September press release. Enrolment is given as 125 in the abstracts against 126 on the registry. A result that moves between presentations is not yet a result. The company's website states NA-931 is in Phase 3. No Phase 3 trial for NA-931 is registered on ClinicalTrials.gov. The announcement traces to a single paid newswire release in January 2026, syndicated into around twenty local newspaper press-release sections, which reads like broad coverage but is one purchased placement.

Trial Progress:Phase III

Pre

III

FDA

Dosing Information

Phase II Completed, Unpublished·Two completed trials, no results posted and no peer-reviewed publications

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

120 mg daily, oral

Range

60-150 mg daily

Frequency

Once daily

Oral, not injectable. The molecule is 154 daltons, far too small for injection to make sense, and any vendor selling it as a reconstitute-and-inject vial is selling the wrong format. The same compound is sold as a consumer supplement.

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

Oral, from trial registrations. No independently published protocol exists.

Doses from Studies

60-150 mg once daily, oral

Trial Registration - NCT06564753, Phase 2 obesity, 126 participants, Australia

Duration

28 days in Phase 1, 13 weeks in Phase 2

Administration

Oral capsule or tablet, once daily

Timing & Administration

Best Time to Take

Consistent daily timing

Once daily

Food Recommendation

With or without food

Why This Timing?

Trials used once-daily oral dosing

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Not FDA approved for any indication
●No peer-reviewed safety data exists
●Company reports diarrhea in 2.3 percent versus 10 percent on placebo, from a conference abstract only
●Cyclic glycine-proline occurs naturally in the body and is sold as a supplement, so acute toxicity is unlikely
●The four-receptor mechanism that would drive weight loss has never been independently confirmed

References

Research This Peptide Further

PubMed ClinicalTrials.gov FDA.gov

Frequently Asked Questions

What does NA-931 do?

NA-931 (Bioglutide) is cyclic glycine-proline, a two-amino-acid ring that occurs naturally as a breakdown product of IGF-1. Its developer, Biomed Industries, describes it as an oral once-daily agonist at four receptors at once - IGF-1, GLP-1, GIP and glucagon - and has reported 13 to 15 percent weight loss in a 126-person Phase 2 trial. Those numbers have only ever appeared in conference abstracts, never in a peer-reviewed paper, and no trial results have been filed to ClinicalTrials.gov. The same molecule is already sold as a consumer brain-health supplement and as a Sigma-Aldrich catalogue chemical, which makes it unusually cheap to source and unusually hard to verify.

How does NA-931 work?

Is NA-931 FDA approved?

No, NA-931 is not currently FDA approved. Current status: Phase 2 completed in Australia April 2025, no results posted. A third trial (NCT06732245) is registered but not yet recruiting. No registered Phase 3 despite company statements. No FDA approval, no orphan designation found, no evidence of a US IND.

What are the side effects of NA-931?

Reported side effects include: Not FDA approved for any indication, No peer-reviewed safety data exists, Company reports diarrhea in 2.3 percent versus 10 percent on placebo, from a conference abstract only, Cyclic glycine-proline occurs naturally in the body and is sold as a supplement, so acute toxicity is unlikely, The four-receptor mechanism that would drive weight loss has never been independently confirmed. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of NA-931?

Community-reported common dose: 120 mg daily, oral (Once daily). Range: 60-150 mg daily. Administration: Oral capsule or tablet, once daily. Trial-registration doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with NA-931 or used in similar applications.

Retatrutide

Clinical Trials

Retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - GIP, GLP-1, and glucagon - earning it the nickname triple-G agonist. In a phase 2 trial it produced some of the largest weight loss ever recorded for a drug, up to roughly 24 percent of body weight at the top dose. It is investigational, made by Eli Lilly, and not yet FDA approved as of 2026.

Weight Loss

Orforglipron

FDA

Orforglipron is Eli Lilly's oral, once-daily GLP-1 receptor agonist, and the headline is that it is a small molecule, not a peptide, so it survives the gut and can be taken as a plain pill with no food or water restrictions. It is being developed for type 2 diabetes and obesity and has completed multiple successful Phase 3 trials. As of mid-2026 it is filed for regulatory review but not yet approved.

Weight Loss

Survodutide

Clinical Trials

Survodutide is an injectable dual agonist that hits both the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. It is being tested for obesity and for fatty liver disease (MASH), and it carries an FDA Breakthrough Therapy designation for MASH. It is still investigational and not approved for any use as of mid-2026.

Weight Loss

Cagrilintide

Clinical Trials

Cagrilintide (also called AM833) is a long-acting synthetic analog of amylin, the gut-brain satiety hormone co-secreted with insulin by pancreatic beta cells. It is an investigational once-weekly injectable being developed by Novo Nordisk for obesity, most prominently as the amylin half of CagriSema (cagrilintide plus semaglutide). It is not yet approved as a standalone drug, but it has cleared phase 2 trials and is in late-stage development.

Weight Loss

Eloralintide

Clinical Trials

Eloralintide (Eli Lilly code LY3841136) is an investigational, long-acting, selective amylin receptor agonist given as a once-weekly subcutaneous injection for obesity. Amylin is the satiety hormone your pancreas releases alongside insulin, and eloralintide is built to mimic it without the gut side effects that sink most appetite drugs. It is not approved anywhere yet, but it has cleared Phase 1 and a 263-person Phase 2 trial with weight loss up to roughly 20 percent, and Lilly has said it is moving into Phase 3.

Weight Loss

Semaglutide

FDA

Semaglutide is a GLP-1 receptor agonist, a peptide engineered to mimic the natural gut hormone GLP-1 but with a roughly week-long half-life so it can be dosed once weekly. It is FDA-approved and sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management, with cardiovascular benefit also on the label. This is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides.

Weight Loss

How to Use NA-931 NA-931 Alternatives Compare with Similar Browse All Peptides

Want updates on NA-931 research?

Get an email when we add new research here, when it is back in stock, or when the price drops.

Back to all peptides